We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+8.72%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$58.1M
AUM Growth
-$17.9M
Cap. Flow
-$4.42M
Cap. Flow %
-7.61%
Top 10 Hldgs %
43.93%
Holding
340
New
63
Increased
59
Reduced
56
Closed
151

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.31M
2
AMGN icon
Amgen
AMGN
+$1.97M
3
IBB icon
iShares Biotechnology ETF
IBB
+$1.79M
4
TSRO
TESARO, Inc.
TSRO
+$1.56M
5
CLX icon
Clorox
CLX
+$1.3M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$5.02M
2
AKBA icon
Akebia Therapeutics
AKBA
+$3.63M
3
FL
Foot Locker
FL
+$2.12M
4
GIS icon
General Mills
GIS
+$2.03M
5
LULU icon
lululemon athletica
LULU
+$1.38M

Sector Composition

Rank Sector Weight
1 Healthcare 37.51%
2 Consumer Staples 17.11%
3 Consumer Discretionary 2.69%
4 Communication Services 1.36%
5 Materials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
126
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
$36K 0.06%
10,200
– –
TDG icon
127
PUT
TransDigm Group
TDG
$67.9B
$36K 0.06%
10,700
-10,000
-48% -$2.54M
PTLA
128
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$36K 0.06%
122,300
+102,300
+512% +$4.1M
GBT
129
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$30K 0.05%
20,000
-8,400
-30% -$250K
SRPT icon
130
PUT
Sarepta Therapeutics
SRPT
$1.82B
$29K 0.05%
+20,000
New +$651K
KPTI icon
131
PUT
Karyopharm Therapeutics
KPTI
$216M
$28K 0.05%
1,333
– –
STZ icon
132
CALL
Constellation Brands
STZ
$22.7B
$28K 0.05%
14,000
+4,700
+51% +$837K
PBYI icon
133
PUT
Puma Biotechnology
PBYI
$434M
$27K 0.05%
61,800
+45,800
+286% +$2.56M
ABBV icon
134
CALL
AbbVie
ABBV
$450B
$26K 0.04%
10,000
-131,900
-93% -$8.87M
VZ icon
135
PUT
Verizon
VZ
$182B
$26K 0.04%
15,000
+5,000
+50% +$233K
PF
136
CALL
DELISTED
Pinnacle Foods, Inc.
PF
$25K 0.04%
+19,700
New +$1.18M
NBIX icon
137
CALL
Neurocrine Biosciences
NBIX
$17.2B
$24K 0.04%
16,000
-2,500
-14% -$121K
IPCI
138
CALL
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$23K 0.04%
+7,200
New +$151K
OZK icon
139
PUT
Bank OZK
OZK
$5.68B
$21K 0.04%
+15,000
New +$713K
QURE icon
140
CALL
uniQure
QURE
$2.77B
$19K 0.03%
102,000
+82,000
+410% +$443K
ESPR
141
PUT
DELISTED
Esperion Therapeutics
ESPR
$17K 0.03%
63,000
-5,000
-7% -$184K
XBI icon
142
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$17K 0.03%
15,000
-15,000
-50% -$1.06M
DISH
143
CALL
DELISTED
DISH Network Corp.
DISH
$17K 0.03%
+24,300
New +$1.53M
COST icon
144
PUT
Costco
COST
$417B
$16K 0.03%
+10,000
New +$1.72M
HOG icon
145
CALL
Harley-Davidson
HOG
$2.8B
$16K 0.03%
+8,500
New +$473K
KHC icon
146
PUT
Kraft Heinz
KHC
$30.7B
$16K 0.03%
+2,000
New +$181K
AGN
147
PUT
DELISTED
Allergan plc
AGN
$16K 0.03%
+12,000
New +$2.82M
PALI icon
148
Palisade Bio
PALI
$342M
– –
0
– –
A icon
149
PUT
Agilent Technologies
A
$37.1B
$13K 0.02%
+10,000
New +$570K
BABA icon
150
PUT
Alibaba
BABA
$276B
$13K 0.02%
10,000
-3,000
-23% -$370K
4 5
6
7 8

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2017 Portfolio in Review

As of Q2 2017, FT Options held 340 positions worth $58.1M, down 24% from $76M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

FT Options withdrew a net $4.42M in Q2 2017, closing 151 positions and reducing 56 holdings. Its most notable exit was Foot Locker, an estimated $2.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, FT Options opened a new position in Amgen worth $2.08M.

  • FT Options's largest Q2 2017 buy was Amgen: 12,082 shares worth $2.08M.
  • FT Options added most to Clovis Oncology, Inc. in Q2 2017, an estimated $2.31M increase.
  • FT Options's biggest Q2 2017 reduction was Abbott, cutting an estimated $5.02M.
  • FT Options fully exited Foot Locker in Q2 2017, selling an estimated $2.12M.
  • FT Options's ten largest holdings make up 44% of its $58.1M portfolio in Q2 2017.
  • FT Options opened 63 new positions and closed 151 in Q2 2017.
  • FT Options's portfolio value fell 24% quarter-over-quarter to $58.1M.

Based on FT Options's 13F filing for Q2 2017, filed 11 Aug 2017.